Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 6/20 | 0.97 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.97 |
| ▸ | TSHR | P16473 | 4/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.73 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 3/20 | 0.62 |
| ▸ | RECQL | P46063 | 3/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.62 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | APEX1 | P27695 | 2/20 | 0.62 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.62 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.62 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Normetanephrine SCHEMBL4949341 | 1.00 | NFKB1 (1.00) | NFKB1BLMPMP22TSHRCYP3A4 | |
| Normetanephrine SCHEMBL29516838 | 1.00 | NFKB1 (1.00) | NFKB1BLMPMP22TSHRCYP3A4 | |
| Normetanephrine SCHEMBL1168235 | 0.98 | BLM (1.00) | NFKB1BLMPMP22TSHRCYP3A4 | |
| Normetanephrine SCHEMBL15421560 | 0.97 | NFKB1 (0.94) | NFKB1BLMPMP22TSHRCYP3A4 | |
| Normetanephrine SCHEMBL11341275 | 0.92 | NFKB1 (0.85) | NFKB1BLMPMP22TSHRCYP3A4 | |
| Normetanephrine SCHEMBL28288010 | 0.91 | NFKB1 (0.83) | NFKB1BLMPMP22TSHRCYP3A4 | |
| Metanephrine SCHEMBL2771744 | 0.90 | NFKB1 (0.81) | NFKB1BLMPMP22TSHRCYP3A4 | |
| SCHEMBL3175780 | 0.86 | NFKB1 (0.74) | NFKB1BLMPMP22TSHRCYP3A4 | |
| Normetanephrine Hydrochloride SCHEMBL7153624 | 0.86 | NFKB1 (0.76) | NFKB1BLMPMP22TSHRCYP3A4 | |
| Normetanephrine Hydrochloride SCHEMBL11573078 | 0.86 | NFKB1 (0.76) | NFKB1BLMPMP22TSHRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1568 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260148848-A1 | BIOMARKERS FOR DIAGNOSIS AND TREATMENT OF ENDOCRINE HYPERTENSION, AND METHODS OF IDENTIFICATION THEREOF | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2026-05-28 | — | — | US | claimed |
| EP-4747627-A1 | METHODS AND SYSTEMS FOR PREDICTIVE CLASSIFICATION BY MASS SPECTROMETRY AND TRAINED LARGE SPECTRAL MODELS | Matterworks Inc (US) | 2026-05-27 | — | — | EP | claimed |
| EP-4704826-A1 | COMPOSITIONS AND METHODS FOR TREATING POST-TRAUMATIC STRESS DISORDER | Yale University (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4704839-A2 | IMIDAZOLE CONTAINING COMPOUNDS, DERIVATIVES THEREFORE, AND USES THEREOF | ALPHERABIO LLC (US) | 2026-03-11 | — | — | EP | claimed |
| US-20250186401-A1 | COMBINATORIAL ACTIVATION OF GABA(B) AND A2 ADRENERGIC RECEPTORS PROVIDES RELIEF FROM STRESS INDUCED DEPRESSION | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2025-06-12 | — | — | US | claimed |
| CN-120114603-A | Compound pharmaceutical composition for treating presbyopia as well as preparation method, application and preparation thereof | 立生医药(苏州)有限公司 | 2025-06-10 | — | — | CN | claimed |
| EP-4562182-A1 | BIOMARKERS FOR DIAGNOSIS AND TREATMENT OF ENDOCRINE HYPERTENSION, AND METHODS OF IDENTIFICATION THEREOF | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2025-06-04 | — | — | EP | claimed |
| CN-119700672-A | An eye spray composition for relieving ptosis and redeye | 立生医药(苏州)有限公司 | 2025-03-28 | — | — | CN | claimed |
| US-20250041211-A1 | OPHTHALMIC PREPARATION AND APPLICATION THEREOF IN TREATMENT OF PRESBYOPIA | Eye Hospital, Wenzhou Medical University (CN) | 2025-02-06 | — | — | US | claimed |
| WO-2025016307-A1 | HEALTH HOMEOSTASIS MODEL, ELASTIC HOMEOSTASIS MODEL, AND USAGE METHOD THEREFOR | 汤臣倍健股份有限公司 | 2025-01-23 | — | — | WO | claimed |
| US-20020182600-A1 | Method for assaying biological and other constituents using synthetic nucleounits in lateral flow, liquid, and dry chemistry techniques | SMITH JACK V (US) | 2002-12-05 | — | — | US | claimed |
| US-6403645-B2 | Antidepressant effect of norepinephrine uptake 2 inhibitors and combined medications including them | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2002-06-11 | — | — | US | claimed |
| US-20020013312-A1 | Antidepressant effect of norepinephrine uptake 2 inhibitors and combined medications including them | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2002-01-31 | — | — | US | claimed |
| WO-2001089448-A2 | COMBINATION OF ADRENERGIC AGONIST AND NMDA ANTAGONIST FOR RELIEVING CHRONIC PAIN WITHOUT ADVERSE SIDE EFFECTS | OLNEY JOHN W (US) | 2001-11-29 | — | — | WO | claimed |
| WO-2001078709-A2 | TREATMENT OF NEURODEGENERATIVE DISEASE | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2001-10-25 | — | — | WO | claimed |
| WO-2001039761-A1 | ADMINISTRATION OF AN ALPHA-2 ADRENERGIC RECEPTOR AGONIST TO ENHANCE CARDIOPULMONARY RESUSCITATION | INSTITUTE OF CRITICAL CARE MEDICINE (US) | 2001-06-07 | — | — | WO | claimed |
| US-4591551-A | ENZYMATIC TRANSMETHYLATION | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 1986-05-27 | — | — | US | claimed |
| US-4287368-A | BY OXIDATION OF METANEPHRINE OR NORMETANEPHRINE WITH A PERIODATE | THE UPJOHN COMPANY (US) | 1981-09-01 | — | — | US | claimed |
| US-4275150-A | FOR MEDICAL DIAGNOSIS OF PHEOCHROMOCYTOMA | VLACHAKIS NICOLAS D | 1981-06-23 | — | — | US | claimed |
| US-4108973-A | OXIDATION | HOFFMANN-LA ROCHE INC. (US) | 1978-08-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260148848-A1 | BIOMARKERS FOR DIAGNOSIS AND TREATMENT OF ENDOCRINE HYPERTENSION, AND METHODS OF IDENTIFICATION THEREOF | SHBG, HSD11B2, HSD11B1 | NFKB1 4396/4885BLM 2676/4885PMP22 3089/4885 |
| US-20250186401-A1 | COMBINATORIAL ACTIVATION OF GABA(B) AND A2 ADRENERGIC RECEPTORS PROVIDES RELIEF FROM STRESS INDUCED DEPRESSION | GABRB2, GABRB1, ADRB2 | NFKB1 1615/4885BLM 3073/4885PMP22 2140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.